Durvalumab, an anti-PD-L1 monoclonal antibody, was studied in the phase III PACIFIC trial and showed prolonged PFS in patients with stage III unresectable NSCLC after concurrent chemo-radiation treatment. The gene discussed is CD274; the disease is non-small cell lung carcinoma.